IL-33, Endocan and Endothelial Cells

Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03984383

Acronym

IL-33

Enrollment

Registered

2019-06-13

Start date

2021-11-08

Completion date

2021-11-08

Last updated

2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endothelial Cell

Keywords

Endothelial cells, inflammation, endothelial dysfunction, IL-33, Endocan

Brief summary

The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants. For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells. Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery. Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * signed consent * Pregnant woman for umbilical cord-derive-endothelial cells

Exclusion criteria

* Age \< 18 years * Refusal to participate to the study * Endothelial cord-drived endothelial cells : * significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) * infection for HIV, VHB, VHC * unknown status for HIV, VHB, VHC the day of the childbirth.

Design outcomes

Primary

Measure	Time frame
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 48 hours after stimulation

Secondary

Measure	Time frame
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in IL33 protein concentration between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in IL33 protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as IL-33 / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours after stimulation
change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in endocan protein concentration between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in endocan protein concentration between stimulated and unstimulated primary human umbilical cord-derived endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation
change in the level of messenger RNA expressed as endocan / GAPDH ratio between stimulated and unstimulated primary human lung endothelial cells.	change from Baseline at 4 hours, 12h ours, 24 hours and 48 hours after stimulation

Countries

France

Outcome results